GBIM (GlobeImmune) 1-Year Share Buyback Ratio : 0.00% (As of Mar. 2016 )

View and export this data going back to 2014. Start your Free Trial

What is GlobeImmune 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. GlobeImmune's current 1-Year Share Buyback Ratio was 0.00%.

GBIM's 1-Year Share Buyback Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: -13.65
* Ranked among companies with meaningful 1-Year Share Buyback Ratio only.

Competitive Comparison of GlobeImmune's 1-Year Share Buyback Ratio

For the Biotechnology subindustry, GlobeImmune's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlobeImmune's 1-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeImmune's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where GlobeImmune's 1-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

GlobeImmune 1-Year Share Buyback Ratio Calculation

GlobeImmune's 1-Year Share Buyback Ratio for the quarter that ended in Mar. 2016 is calculated as

1-Year Share Buyback Ratio	=	(Shares Outstanding (EOP) (Mar. 2015 )	-	Shares Outstanding (EOP) (Mar. 2016 ))	/	Shares Outstanding (EOP) (Mar. 2015 )
	=	(5.752	-	5.752)	/	5.752
	=	0.0%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlobeImmune (OTCPK:GBIM) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

GlobeImmune 1-Year Share Buyback Ratio Related Terms

GlobeImmune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeImmune Inc (OTCPK:GBIM) » Definitions » 1-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

1450 Infinite Drive, Louisville, CO, USA, 80027

Website

https://globeimmune.com

GlobeImmune Inc is a U.S.-based biopharmaceutical company which focuses on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen platform. It develops few Tarmogen product candidates for infectious disease and multiple cancer indications. The pipeline products of the company are GS-4774, GI-19000, GI-2010, GI-18000 which targets HBV and HIV antigens, TB antigens and Delta virus antigens and Oncology product candidates such as GI-6207, GI-6301, GI4000 which targets Carcinoembryonic antigen, Brachyury, and Mutated Ras.

Executives

Augustine Lawlor	director	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Daniel J Mitchell	director
S. Edward Torres	director	C/O LILLY VENTURES FUND I LLC, 115 W. WASHINGTON ST, STE 1680 SOUTH, INDIANAPOLIS IN 46204
Healthcare Ventures Vii Lp	other: Former 10% Owner	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
John W Littlechild	other: Former 10% Owner	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
James H Cavanaugh	other: Former 10% Owner	265 HOTHORPE LANE, VILLANOVA PA 19085
Harold R Werner	other: Former 10% Owner	C/O HEALTHCARE VENTURES LLC, 44 NASSAU STREET, PRINCETON NJ 08542
Christopher Mirabelli	other: Former 10% Owner	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Healthcare Partners Vii, L.p.	other: Former 10% Owner	44 NASSAU STREET, PRINCETON NJ 08542
J William Freytag	director
Rodell Timothy C Jr	director, officer: CEO & Pres	201 MIDLAND AVE, ASPEN CO 81611
Celgene Corp /de/	10 percent owner	86 MORRIS AVENUE, SUMMIT NJ 07901
Morgenthaler Partners Vii Lp	10 percent owner	50 PUBLIC SQUARE, SUITE 2700, CLEVELAND OH 44113

GlobeImmune Headlines

No Headlines